Valuation : Sprint Bioscience AB

Market Cap 34Cr 3.59Cr 3.09Cr 2.9Cr 2.65Cr 4.96Cr 339Cr 4.98Cr 13Cr 173.67Cr 13Cr 13Cr 564.02Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 34Cr 3.59Cr 3.09Cr 2.9Cr 2.65Cr 4.96Cr 339Cr 4.98Cr 13Cr 173.67Cr 13Cr 13Cr 564.02Cr EV / Sales 2026 *
3.95x
EV / Sales 2027 * 3.54x
Free-Float
72.16%
Yield 2026 *
-
Yield 2027 * -
1 day-1.22%
1 week+2.20%
Current month+1.56%
1 month-6.61%
3 months-5.25%
6 months+71.50%
Current year+121.09%
1 week 3.1
Extreme 3.1
3.38
1 month 2.77
Extreme 2.77
3.59
Current year 1.36
Extreme 1.355
4.59
1 year 0.51
Extreme 0.512
4.59
3 years 0.36
Extreme 0.36
4.59
5 years 0.36
Extreme 0.36
5.4
10 years 0.36
Extreme 0.36
41.5
Manager TitleAgeSince
Chief Executive Officer 42 01/10/2023
Chief Tech/Sci/R&D Officer 55 01/01/2009
Director of Finance/CFO 55 04/05/2026
Director TitleAgeSince
Chairman 70 01/01/2010
Director/Board Member 50 01/01/2019
Chairman 58 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
-1.22%+2.20%+432.79%+8.70% 3.58Cr
-1.79%-2.27%+43.23%+88.96% 6.8TCr
-2.06%-0.18%+39.67%+86.44% 6.49TCr
-0.31%+6.54%-12.96%+378.92% 2.76TCr
+0.86%+1.65%-7.74%-14.95% 2.61TCr
-3.00%-2.90%+33.13%+12.54% 2.57TCr
-1.46%+0.42%+23.61%-18.61% 2.01TCr
-2.96%-15.21%+216.20%+368.10% 1.72TCr
-1.49%-4.88%-6.60%+531.89% 1.49TCr
-0.20%+8.37%+55.78%+164.98% 1.46TCr
Average -1.36%+0.45%+81.71%+160.70% 2.79TCr
Weighted average by Cap. -1.52%+0.18%+38.42%+137.33%

Financials

2026 *2027 *
Net sales 8.68Cr 90.78L 78.12L 73.47L 67.11L 1.26Cr 86Cr 1.26Cr 3.37Cr 44Cr 3.41Cr 3.33Cr 142.76Cr 9.68Cr 1.01Cr 87.12L 81.94L 74.84L 1.4Cr 96Cr 1.41Cr 3.75Cr 49Cr 3.8Cr 3.72Cr 159.21Cr
Net income - -
Net Debt - -
Logo Sprint Bioscience AB
Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
Employees
30
Date Price Change Volume
04/26/04 SEK 3.250 -1.22% 1,73,438
03/26/03 SEK 3.290 +0.30% 1,10,005
02/26/02 SEK 3.280 -0.61% 3,12,923
01/26/01 SEK 3.300 +3.12% 2,68,442
31/26/31 SEK 3.200 +0.63% 1,78,120

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRINT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!